164 related articles for article (PubMed ID: 18071675)
1. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.
Krzyzanski W; Wyska E
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):637-45. PubMed ID: 18071675
[TBL] [Abstract][Full Text] [Related]
2. A Full Target-Mediated Drug Disposition (TMDD) Model to Explain the Changes in Recombinant Human Erythropoietin (rhEpo) Pharmacokinetics in Patients with Different Bone Marrow Integrity Following Hematopoietic Transplantation.
Wu N; Widness JA; Yan X; Veng-Pedersen P; An G
J Pharm Sci; 2022 Sep; 111(9):2620-2629. PubMed ID: 35691608
[TBL] [Abstract][Full Text] [Related]
3. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).
Woo S; Krzyzanski W; Jusko WJ
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):849-68. PubMed ID: 17943422
[TBL] [Abstract][Full Text] [Related]
4. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.
El-Komy MH; Schmidt RL; Widness JA; Veng-Pedersen P
Biopharm Drug Dispos; 2011 Jul; 32(5):276-88. PubMed ID: 21678432
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.
El-Komy MH; Widness JA; Veng-Pedersen P
Drug Metab Dispos; 2011 Apr; 39(4):603-9. PubMed ID: 21209249
[TBL] [Abstract][Full Text] [Related]
6. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
7. In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography.
Fuge F; Doleschel D; Rix A; Gremse F; Wessner A; Winz O; Mottaghy F; Lederle W; Kiessling F
Eur Radiol; 2015 Feb; 25(2):472-9. PubMed ID: 25196361
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
J Pharmacol Exp Ther; 2010 Sep; 334(3):897-910. PubMed ID: 20501635
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes.
Pan Y; Shu JL; Gu HF; Zhou DC; Liu XL; Qiao QY; Fu SK; Gao FH; Jin HM
Mol Cell Endocrinol; 2013 Mar; 367(1-2):116-23. PubMed ID: 23313788
[TBL] [Abstract][Full Text] [Related]
11. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
Exp Hematol; 2001 Apr; 29(4):425-31. PubMed ID: 11301182
[TBL] [Abstract][Full Text] [Related]
12. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
Yan X; Ruixo JJP; Krzyzanski W
AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
[TBL] [Abstract][Full Text] [Related]
13. Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology.
Torregrossa F; Aguennouz M; La Torre D; Sfacteria A; Grasso G
World Neurosurg; 2019 Nov; 131():346-355. PubMed ID: 31658577
[TBL] [Abstract][Full Text] [Related]
14. The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis, and phosphorylation.
Sawyer ST; Hankins WD
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6849-53. PubMed ID: 8341708
[TBL] [Abstract][Full Text] [Related]
15. Hyperhydration Effect on Pharmacokinetic Parameters and Detection Sensitivity of Recombinant Human Erythropoietin in Urine and Serum Doping Control Analysis of Males.
Athanasiadou I; Dokoumetzidis A; Voss SC; El Saftawy W; Al-Maadheed M; Valsami G; Georgakopoulos C
J Pharm Sci; 2019 Jun; 108(6):2162-2172. PubMed ID: 30684541
[TBL] [Abstract][Full Text] [Related]
16. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
LaMontagne KR; Butler J; Marshall DJ; Tullai J; Gechtman Z; Hall C; Meshaw A; Farrell FX
Mol Cancer Ther; 2006 Feb; 5(2):347-55. PubMed ID: 16505108
[TBL] [Abstract][Full Text] [Related]
17. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury.
Salahudeen AK; Haider N; Jenkins J; Joshi M; Patel H; Huang H; Yang M; Zhe H
Am J Physiol Renal Physiol; 2008 Jun; 294(6):F1354-65. PubMed ID: 18385271
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
Miura O; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
Blood; 1994 Sep; 84(5):1501-7. PubMed ID: 8068943
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
Egrie JC; Dwyer E; Browne JK; Hitz A; Lykos MA
Exp Hematol; 2003 Apr; 31(4):290-9. PubMed ID: 12691916
[TBL] [Abstract][Full Text] [Related]
20. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
